Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
|Articles|October 14, 2020
Omnicell rebrands unit with mission to raise quality at lower cost for providers and payers
EnlivenHealth, formerly Population Health Solutions, targets better patient outcomes through advanced technology
Advertisement
Omnicell, Inc. is rebranding its Population Health Solutions division into EnlivenHealth, a unit dedicated to enabling retail pharmacies and health plans to improve patient outcomes while reducing costs through software-as-a-service technology.
The newly named division serves nearly 30,000 retail pharmacies across the country, delivering patient engagement and personalized communications tools to pharmacists.
Technology services offered include medication synchronization designed to align prescription refills to a single date each month, communications programs that help pharmacies and health plans streamline workflow and create personalized patient care, and at the same time support patient satisfaction and retention.
“The mission of EnlivenHealth is fundamentally about bending the quality and cost curve for healthcare providers and payers,” according to Randall Lipps, chairman, president, CEO and founder of Omnicell. He added that the company’s vision aims to leverage data intelligence, and drive workflow automation, digitization and optimization.
Other EnlivenHealth services include medication therapy management, interactive voice response, patient adherence, opioid mitigation and tailored population health programs.
Advertisement
Related to this article
At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.
PAXAFE's Mark Talens explains why real-time visibility starts with process redesign and how it speeds cold chain disposition decisions.
Epic's Prescription Marketplace, due summer 2027, will show pharmacy cash prices next to insured costs before a prescription is sent.
Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as agentic AI raises the governance stakes.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
Inizio Ignite leaders argue static, milestone-driven launch plans fall short and AI sharpens execution only when built on a sound strategy.
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How CMS’ Final Negotiation Rule Treats New Drug Formulations
2
Big Three Distributors Lean on Specialty for Profit Growth
3
The AI Efficiency Trap: Why Faster Tasks Alone Won’t Transform Life Sciences
4
Bob Cochran: Direct-to-Patient Was a 'Watershed Moment' for Commercial Trade
5